Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2
James Brett Case, Paul W. Rothlauf, Rita E. Chen, Zhuoming Liu, Haiyan Zhao, Arthur S. Kim, Louis-Marie Bloyet, Qiru Zeng, Stephen Tahan, Lindsay Droit, Ma. Xenia G. Ilagan, Michael A. Tartell, Gaya K. Amarasinghe, Jeffrey P. Henderson, Shane Miersch, Mart Ustav, Sachdev S. Sidhu, Herbert W. Virgin, David Wang, Siyuan Ding, Davide Corti, Elitza S. Theel, Daved H. Fremont, Michael Diamond, Sean P. J. Whelan
Topics & Concepts
BiologyVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntibodyCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakViral replicationReplication (statistics)Neutralizing antibodySars virusMicrobiologyImmunologyVirusInfectious disease (medical specialty)MedicineDiseasePathologyOutbreakSARS-CoV-2 and COVID-19 ResearchViral Infections and Immunology ResearchVirus-based gene therapy research